Skip to main content
VCbacked
Log inGet Started

Alamar Biosciences

Fremont, United States

Powering precision proteomics to enable to the earliest detection of disease.

$50.0M raised
Jan 2026
Convertible Note
BiotechnologyHealth CareLife ScienceMedical

Top Investors

Qiming Venture PartnersSamsara BioCapitalSands Capital VenturesSherpa Healthcare PartnersIllumina Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Alamar Biosciences

How much funding has Alamar Biosciences raised?
Alamar Biosciences has raised $50.0M in total funding. The most recent round was Convertible Note. The last funding was announced in January 2026.
Who are Alamar Biosciences's investors?
Alamar Biosciences's investors include Qiming Venture Partners, Samsara BioCapital, Sands Capital Ventures, Sherpa Healthcare Partners, Illumina Ventures.
Where is Alamar Biosciences headquartered?
Alamar Biosciences is headquartered in Fremont, United States.
What does Alamar Biosciences do?
Powering precision proteomics to enable to the earliest detection of disease.
What stage is Alamar Biosciences at?
Alamar Biosciences is at the Convertible Note stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Alamar Biosciences — Funding & Investors." VCBacked, January 11, 2026, https://www.vcbacked.co/company/alamar-biosciences. Accessed June 3, 2026.
APA
VCBacked. (2026). Alamar Biosciences — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/alamar-biosciences
Wikipedia (cite web)
{{cite web |title=Alamar Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/alamar-biosciences |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong